It is very uncertain whether methotrexate changes adverse events (Ardizzone 2003) compared with 6‐MP or azathioprine (very low certainty).
It is very uncertain whether methotrexate + infliximab changes adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
Azathioprine or 6‐mercaptopurine may leads to lower adverse events compared with methotrexate (low certainty).
It is very uncertain whether 6‐Mercaptopurine changes adverse events compared with methotrexate (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes serious adverse events compared with methotrexate (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).